NASDAQ:SPRC SciSparc (SPRC) Stock Price, News & Analysis $4.46 +0.18 (+4.21%) Closing price 04:00 PM EasternExtended Trading$5.84 +1.38 (+30.85%) As of 05:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsFDA EventsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock About SciSparc Stock (NASDAQ:SPRC) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get SciSparc alerts:Sign Up Key Stats Today's Range$4.18▼$4.5450-Day Range$1.80▼$8.1952-Week Range$1.75▼$37.59Volume4.62 million shsAverage Volume1.51 million shsMarket Capitalization$2.36 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview SciSparc AG is a clinical‐stage medical technology company focused on the development and commercialization of extracorporeal shock wave–based neuromodulation devices. Founded in 2016 and headquartered in Switzerland, the company applies proprietary low‐intensity shock wave technology to noninvasively stimulate neural tissue. SciSparc completed its initial public offering on the NASDAQ in 2021 under the ticker SPRC, securing funding to advance its clinical pipeline. The company’s lead product, the TR100 system, delivers transcranial shock wave stimulation (tSWS) designed to target areas of the brain associated with motor control and cognitive function. By harnessing acoustic pressure waves, the TR100 aims to promote neurogenesis and synaptic plasticity without the need for surgical intervention. SciSparc has obtained CE marking for its tSWS platform in the European Union and is actively pursuing clinical trials in indications such as post‐stroke motor rehabilitation, treatment‐resistant depression and other neurological disorders. Serving both European and North American markets, SciSparc collaborates with academic institutions and clinical research centers to validate safety and efficacy in human subjects. Its Swiss headquarters oversees research and development, regulatory affairs and manufacturing partnerships, while its U.S. operations concentrate on clinical development and market access strategies. By integrating neuroscience research with advanced engineering, SciSparc aims to expand the availability of noninvasive neuromodulation therapies on a global scale.AI Generated. May Contain Errors. Read More SciSparc Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks7th Percentile Overall ScoreSPRC MarketRank™: SciSparc scored higher than 7% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for SciSparc. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioSciSparc has a P/B Ratio of 0.24. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted28.23% of the float of SciSparc has been sold short.Short Interest Ratio / Days to CoverSciSparc has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in SciSparc has recently increased by 1,223.68%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSciSparc does not currently pay a dividend.Dividend GrowthSciSparc does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted28.23% of the float of SciSparc has been sold short.Short Interest Ratio / Days to CoverSciSparc has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in SciSparc has recently increased by 1,223.68%, indicating that investor sentiment is decreasing significantly. News and Social Media3.0 / 5News Sentiment0.35 News SentimentSciSparc has a news sentiment score of 0.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.02 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 14 news articles for SciSparc this week, compared to 1 article on an average week.Search Interest7 people have searched for SPRC on MarketBeat in the last 30 days. This is an increase of 250% compared to the previous 30 days.MarketBeat Follows1 people have added SciSparc to their MarketBeat watchlist in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, SciSparc insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.52% of the stock of SciSparc is held by insiders.Percentage Held by InstitutionsOnly 25.06% of the stock of SciSparc is held by institutions.Read more about SciSparc's insider trading history. Receive SPRC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SciSparc and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SPRC Stock News HeadlinesSciSparc: N2OFF Shareholders Approve Merger with SciSparc's Majority Owned Subsidiary MitoCareX, a Drug Discovery Company Targeting Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer2 hours ago | globenewswire.comSciSparc Ltd. Announces Warrant Exercise AgreementSeptember 26 at 9:31 AM | tipranks.comHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvidia at $1.10 reveals AI’s Next Magnificent Seven… including one stock he says could become America’s next trillion-dollar giant.September 29 at 2:00 AM | The Oxford Club (Ad)SciSparc Stock Soared 61% Today – Here’s An Important UpdateSeptember 25, 2025 | msn.comSciSparc initiate launch of 3D protein modeling initiativeSeptember 25, 2025 | msn.comSciSparc stock soars after launching quantum computing initiativeSeptember 25, 2025 | investing.comSciSparc Shares Surge Following Launch of Quantum Computing ProgramSeptember 25, 2025 | msn.comSciSparc Ltd. Launches Initiative to Advance 3D Protein Modeling with Quantum Computing TechnologySeptember 25, 2025 | quiverquant.comQSee More Headlines SPRC Stock Analysis - Frequently Asked Questions How have SPRC shares performed this year? SciSparc's stock was trading at $7.56 at the start of the year. Since then, SPRC stock has decreased by 41.6% and is now trading at $4.4150. When did SciSparc's stock split? Shares of SciSparc reverse split on the morning of Thursday, July 3rd 2025.The 1-21 reverse split was announced on Tuesday, June 24th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, July 2nd 2025. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of SciSparc? Shares of SPRC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of SciSparc own? Based on aggregate information from My MarketBeat watchlists, some other companies that SciSparc investors own include Solid Power (SLDP), Sangamo Therapeutics (SGMO), Plug Power (PLUG), NVIDIA (NVDA), Verb Technology (VERB) and Avalon GloboCare (ALBT). Company Calendar Today9/29/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SPRC CIK1611746 Webscisparc.com Phone972-3717-5777FaxN/AEmployees4Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio5.36 Quick Ratio5.28 Sales & Book Value Annual Sales$1.31 million Price / Sales1.79 Cash FlowN/A Price / Cash FlowN/A Book Value$18.13 per share Price / Book0.24Miscellaneous Outstanding Shares530,000Free Float527,000Market Cap$2.34 million OptionableNot Optionable Beta0.86 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (NASDAQ:SPRC) was last updated on 9/29/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | Sponsored2013 Bitcoin miner reveals his trading system (free)There are 18,347 cryptocurrencies in the market right now. 99% of them will fail. And trying to pick winner...Crypto Swap Profits | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SciSparc Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share SciSparc With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.